

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

**VOLUNTARY ANNOUNCEMENT
UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS
BUSINESS UPDATES**

The following announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Unusual Price and Trading Volume Movements

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has noted the increases in both the price and trading volume of the H shares of the Company listed on The Stock Exchange of Hong Kong Limited (the “**H Shares**”) on March 13, 2023. Having made appropriate enquiries, the Board confirms that it is not aware of any reasons for such unusual price and trading volume movements of its H Shares or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The Board would also like to take this opportunity to provide the following business updates.

Inclusion as a Constituent of the Hang Seng Composite Index and the Shanghai-Hong Kong Stock Connect Program

According to the Index Review Results published by the Hang Seng Indexes Company Limited in February 2023, the Company was included as a constituent stock of the Hang Seng Composite Index with effect from March 13, 2023. Effective from the same day, our H Shares have been included in the list of Hong Kong Stock Connect stocks under the Shanghai-Hong Kong Stock Connect program. As a result, eligible mainland China investors are now allowed to trade our H Shares subject to a certain amount of daily quota.

Bivalent Delta-Omicron BA.5 mRNA COVID-19 Vaccine Candidate Obtained Phase III Clinical Trial Approval in Pakistan

On March 11, 2023, the Group's bivalent mRNA vaccine candidate against the Delta and Omicron BA.5 variants of COVID-19 (the "**Bivalent Delta-Omicron BA.5 mRNA COVID-19 Vaccine Candidate**") was officially approved to commence Phase III clinical trials in Pakistan.

Previously, we conducted two clinical studies in mainland China of our Bivalent Delta-Omicron BA.5 mRNA COVID-19 Vaccine Candidate, which produced positive results. The subjects in these two clinical studies are persons over 18 years of age who had not received any COVID-19 vaccination and had not been infected with COVID-19 virus. The clinical studies showed that this vaccine candidate has a good safety profile, with the majority of adverse effects being mild and moderate. Furthermore, results of the live virus neutralizing antibody tests showed that the vaccine candidate induced high levels of neutralizing antibodies against the Delta, Omicron BA.5, BQ.1 and XBB variants of COVID-19.

Shareholders of the Company and investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, March 14, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive Directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive Directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive Directors.